This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Pardes Biosciences Past Earnings Performance

Past criteria checks 0/6

Pardes Biosciences's earnings have been declining at an average annual rate of -1.6%, while the Biotechs industry saw earnings growing at 23.7% annually.

Key information

-1.60%

Earnings growth rate

45.77%

EPS growth rate

Biotechs Industry Growth	17.04%
Revenue growth rate	n/a
Return on equity	-49.00%
Net Margin	n/a
Last Earnings Update	30 Jun 2023

Recent past performance updates

No updates

Recent updates

Analysis Article • Jul 18

We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Jan 20

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Oct 01

We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Sep 13

Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19

Pardes Biosciences (NASDAQ:PRDS) said it began a phase 2 trial of oral drug PBI-0451 to treat non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness. The company expects to enroll 210 patients in the study at ~75 sites in the U.S. to evaluate antiviral activity, safety, and efficacy of PBI-0451, compared to placebo. The main goal will be to determine the proportion of patients below the detection limit (in nasal swab samples) for infectious SARS-CoV-2, on day three, the company said in a Sept. 13 press release. "PBI-0451 has the potential to be a stand-alone SARS-CoV-2 protease inhibitor that can be easily prescribed and administered to alleviate the burden of COVID-19 to patients and healthcare systems," said Pardes Chair and CEO Tom Wiggans. The company expects interim data from the study in Q1 2023.

Seeking Alpha • Aug 15

Pardes Biosciences GAAP EPS of -$0.48

Pardes Biosciences press release (NASDAQ:PRDS): Q2 GAAP EPS of -$0.48. Pardes’ cash and cash equivalents as of June 30, 2022, were $228.6M compared to $247.9M as of March 31, 2022. The company expects that the cash and cash equivalents it had on hand as of June 30, 2022, will be sufficient to fund operating expenses and capital expenditures into the second half of 2023.

Analysis Article • Jun 14

Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jan 21

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

Pardes Biosciences is developing a novel coronavirus protease inhibitor platform that is extendable to other variants and viruses. The company’s lead candidate demonstrated selective activity against multiple coronaviruses, including SARS-CoV-2 and its variants, and other viruses like SARS, MERS, and even related to common cold. The company recently consummated a business combination and began trading on NASDAQ from 12/27/2021.

Revenue & Expenses Breakdown

How Pardes Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:PRDS Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Jun 23	-76	26	57
31 Mar 23	-93	28	70
31 Dec 22	-97	29	70
30 Sep 22	-87	27	61
30 Jun 22	-75	23	52
31 Mar 22	-55	17	38
31 Dec 21	-39	10	28
30 Sep 21	-36	7	21
30 Jun 21	-27	4	15
31 Mar 21	-20	2	9

Quality Earnings: PRDS is currently unprofitable.

Growing Profit Margin: PRDS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PRDS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PRDS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).

Return on Equity

High ROE: PRDS has a negative Return on Equity (-49%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/09/01 22:37
End of Day Share Price	2023/08/30 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pardes Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Douglas Buchanan	Citizens JMP Securities, LLC
Yuchen Ding	Jefferies LLC
Roanna Clarissa Ruiz	Leerink Partners LLC